Chronic lymphocytic leukaemia trials in Italy

In Italy 46 Also abroad 308

46 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in Italy
Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies
Where
Milan
Age
18 years and over
People
64
Run by
IRCCS San Raffaele
See details and how to joinNCT07759661
Phase 1Taking people
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
Where
Brescia, Milan, Perugia
Age
18 years and over
People
54 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2022-501876-24-00 · EU 2022-501876-24-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Bologna, Brescia, Milan, Rome
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 3Taking people
Global Trial in APG2575 for Patients With CLL/SLL
Where
Aviano, Brescia, Ferrara, Genoa, Lecce, Meldola, Milan, Padova, Perugia, Piacenza, Ravenna, Reggio Emilia, Rimini, Rome, Rozzano, Turin, Varese
Age
18 years to 99 years
People
400 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00
Phase 2Taking people
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Where
Milan, Novara, Padova
Age
18 years and over
People
108 worldwide
Run by
Curis, Inc.
See details and how to joinNCT07271667 · EU 2025-523600-68-00
Phase 3Taking people
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Where
Candiolo, Florence, Genoa, Parma, Pavia, Ravenna, Rome, Terni
Age
18 years and over
People
250 worldwide
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07139873 · EU 2025-522669-32-00
Phase 2Taking people
Zanubritnib and anti-MAG neuropathy
Where
Genoa, Milan, Padova, Pavia, Rome, Rozzano, Trieste, Turin
Age
18 years and over
People
50
Run by
Azienda Ospedaliera di Padova
See details and how to joinNCT07392229 · EU 2025-523091-23-00
Phase 4Taking people
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Where
Bologna, Milan
Age
18 years and over
People
787 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06876649
Phase 4Taking people
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Where
Bologna, Milan
Age
18 years and over
People
279 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06876662
No phaseTaking people
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Where
Palermo, Perugia
Age
1 year and over
People
300
Run by
Azienda Ospedaliero-Universitaria di Parma
See details and how to joinNCT07403630
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Alexandria, Milan, Turin, Verona
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 2Taking people
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Where
Terni, Turin
Age
18 years and over
People
75 worldwide
Run by
AbbVie
See details and how to joinNCT04895436 · EU 2023-504599-10-00
No phaseTaking people
LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION
Where
Bologna
Age
18 years and over
People
350
Run by
IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT07313982
No phaseTaking people
Study on the Diagnosis and Management of CLL in Italy by GIMEMA
Where
Alessandria, Brescia, Brindisi, Candiolo, Florence, Messina, Mestre, Milan, Piacenza, Ragusa, Roma, Salerno, San Giovanni Rotondo, Siena, Terni, Torino, Treviso, Trieste, Vicenza
Age
18 years and over
People
12,500
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT04867915
Phase 2Taking people
Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia
Where
Brescia, Milan, Padova, Palermo, Terni, Turin
Age
18 years and over
People
53
Run by
Ospedale San Raffaele S.r.l.
See details and how to join2024-514824-18-00 · EU 2024-514824-18-00
No phaseNot yet taking people in Italy
Biological and Clinical Efficacy of Shingrix in Patients With CLL
Where
Varese
Age
18 years and over
People
312
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT06364033
Phase 1/2Taking people
Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia
Where
Bergamo, Monza
Age
1 year and over
People
29
Run by
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
See details and how to joinNCT05869279 · EU 2023-505511-20-00
Phase 2Taking people
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Where
Alessandria, Bari, Brescia, Cagliari, Castelfranco Veneto, Catania, Cosenza, Cuneo, Ferrara, Florence, Genoa, Lecce, Milan, Milano, Modena, Novara, Padova, Parma, Pavia, Perugia, Reggio Calabria, Rome, Trieste, Turin, Varese, Verona
Age
18 years and over
People
45
Run by
Gruppo Italiano Malattie EMatologiche dell'Adulto
See details and how to joinNCT05694312 · EU 2023-509793-38-00
Phase 2Taking people
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
Where
Milan
Age
18 years to 65 years
People
55
Run by
Paolo Ghia
See details and how to joinNCT04758975
Phase 2Taking people
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL
Where
Milan
Age
18 years and over
People
53
Run by
Paolo Ghia
See details and how to joinNCT04908228
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Aviano, Meldola, Milan, Pavia, Verona
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394